[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:vascular-malformation":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":41,"states":42},"Vascular malformation",5,4,[8,16,22,28,34],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06789913","A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)",[12],"Phase 2","RECRUITING","2026-08-26T02:17:21.315591Z","2026-07-05T05:32:16.695791Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT04104464","Patient Reported Outcomes for Vascular Malformations EmbolizatioN (PROVEN)",[],"2026-08-26T02:18:11.042248Z","2026-05-13T02:55:06.240984Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT03001180","Identification of Biomarkers for Patients with Vascular Anomalies",[],"2026-08-26T02:17:57.117858Z","2026-05-13T02:55:06.106471Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT02399527","Lymphatic Anomalies Registry for the Assessment of Outcome Data",[],"2026-08-26T02:18:21.216897Z","2026-05-13T02:55:06.093747Z",{"nct_id":35,"title":36,"phases":37,"status":38,"updated_at":39,"content_modified":40},"NCT00833599","Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders",[],"ENROLLING_BY_INVITATION","2026-08-26T02:16:46.147215Z","2026-06-16T05:54:07.944228Z",[],[43],{"state":44,"count":45,"slug":46},"Massachusetts",3,"massachusetts"]